Drug Trial News

RSS

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

The National Institutes of Health (NIH) has awarded United Therapeutics Corporation a contract for up to $45 million over five years "to help develop a potential oral treatment for viruses like influenza and the mosquito-borne tropical fever dengue," the Associated Press/Washington Post reports.

12 Oct 2011

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.

12 Oct 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

COPAXONE reduces loss of brain volume in patients with RRMS

Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study

BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.

11 Oct 2011

Omeros initiates OMS302 Phase 3 trial in intra-ocular lens replacement surgery

Omeros Corporation today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery.

11 Oct 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Aduro BioTech, Inc. announces the treatment of the first patient in the Phase 2 pancreatic cancer clinical trial of the sequential administration of two cancer vaccines: Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Roche's gantenerumab removes amyloid plaques from the brain of patients with AD

Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.

11 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

11 Oct 2011

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

DNA vaccine development company Coridon Pty Ltd. today announced that it had successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results. The company will now look to progress the program into clinical studies.

10 Oct 2011

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer's disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration.

10 Oct 2011

Unither Virology receives NIAID contract for glycobiology antiviral platform

United Therapeutics Corporation announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

10 Oct 2011